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Real-time detection of carboplatin using a
microﬂuidic system†
Tonghathai Phairatana,a,b Chi Leng Leong,b Sally A. N. Gowers,b Bhavik Anil Patelc
and Martyn G. Boutelle*b
A microﬂuidic sensor system based on a carbon nanotube-epoxy composite electrode was fabricated to
allow detection of the presence of the anti-cancer drug carboplatin in healthy tissue in real time during
chemotherapy. Detection of carboplatin was carried out by observing the eﬀects of the drug on the
diﬀerential pulse voltammetry of free purine bases using a novel carbon nanotube-epoxy composite elec-
trode. In free solution these electrodes performed better than glassy carbon electrodes for oxidation of
the free purine bases AMP and GMP, and than DNA-modiﬁed carbon nanotube-epoxy composite sensors
for detection of carboplatin. On-line carboplatin detection was performed using a computer-controlled
microﬂuidic platform. The methodology for on-line carboplatin detection was optimised in terms of the
analysis time and to allow repeated carboplatin measurement using the same electrode. Microdialysis
sampling and our microﬂuidic platform were combined to give a proof-of-concept system for real-time
carboplatin detection with a limit of detection of 0.014 μM carboplatin in the sampled media. This paper
is dedicated to Craig Lunte’s pioneering work in analysis and microdialysis.
1 Introduction
Chemotherapy is central to most cancer treatment regimes. It
usually involves systemic administration of one or more anti-
cancer drugs, which are designed to kill cancer cells and
hence inhibit the growth of tumours in order to prevent their
spread to other organs. Platinum-based anti-cancer drugs such
as oxaliplatin, nedaplatin, lobaplatin, heptaplatin and carbo-
platin are used for chemotherapy.1 Among these drugs, carbo-
platin is most widely used for the treatment of a variety of
malignancies. Carboplatin has proven activity against a variety
of solid tumours including ovarian, testicular, head and neck
and lung cancers (both non-small-cell and small-cell).2–6
However, although carboplatin is an eﬀective anti-cancer drug,
it causes many side eﬀects. This is because, in common with
all anti-cancer drugs, carboplatin works by binding to the DNA
of active cells that are growing and dividing and as a result it
cannot distinguish between cancer cells and healthy cells such
as blood cells, skin cells, hair follicles and the cells inside the
digestive system. Consequently, carboplatin aﬀects not only
the cancer cell growth but also blocks the growth of healthy
rapidly dividing cells, leading to side eﬀects such as mouth
and throat sores, diarrhea, nausea and vomiting, blood dis-
orders, nervous system eﬀects, appetite loss and hair loss.7,8
Several analytical techniques have been used to detect the
interaction of carboplatin with the structure of deoxyribo-
nucleic acid (DNA). These include high-performance liquid
chromatography, inductively coupled plasma-mass spec-
trometry and capillary electrophoresis.9–13 These methods
involve large instruments with high costs, require highly-
trained personnel for testing and as they are sample-based
give poor time resolution. There is a need for rapid, continu-
ous, low-cost techniques for analysis of drug–DNA interaction
and high time resolution. Electrochemical techniques have
high sensitivity, low cost, and rapid response. Typically once
the method is established they do not require a great deal of
user expertise. This has made electrochemical devices an
attractive choice for point-of-care applications with high time
resolution.
Carboplatin is not electroactive and therefore cannot be
detected directly using electrochemistry, however, it can be
detected through its eﬀect on DNA bases, which are electroche-
mically active. These interactions have been studied with a
range of electrodes including hanging mercury drop electro-
des, screen printed electrodes, graphite electrodes and glassy
carbon electrodes.14–17 Carboplatin has been detected electro-
chemically through its eﬀects on DNA electrochemistry by the
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Brett-Oliveira group using glassy carbon electrode (GCE).17
Initially, the GCE was coated with DNA to detect the oxidation
peaks due to four DNA bases (adenine, guanine, cytosine and
thymine),18 of these only guanine and adenine respond to
carboplatin. It was also necessary to condition the DNA sensors
in single-stranded (ss) DNA (forming a triplex structure) to
stabilise DNA-base oxidation peaks.19
The problem with carboplatin is that its therapeutic index
(the ratio between eﬀective dose and toxic dose) is low.
Consequently, avoiding toxicity by controlling the systemic
dose is diﬃcult. Recently, there has been a move to bioengi-
neer devices that allow personalisation of cancer treatment by
applying the drugs either singly or in combination directly to
the tissue.20 At present these approaches use histology to
determine drug eﬀectiveness followed potentially by systemic
administration of the drugs.21,22 An alternative approach is to
consider treatment by delivering the drug directly to a targeted
specific area (the tumour) at a high dose and to monitor the
surrounding healthy tissue for the first arrival of the drug.
This could be achieved either by detecting carboplatin or DNA
damage caused by carboplatin in real time. Such an approach
could enhance the eﬀectiveness of chemotherapy, would
reduce side eﬀects and would also reduce the cost of drug
administration as the drug would be injected directly into the
cancer cells.
Microdialysis (MD) is a powerful sampling technique that is
capable of continuously monitoring the extracellular space
both in vivo and in vitro. MD sampling has been used exten-
sively for monitoring amino acids, neurotransmitters and
energy metabolites such as glucose, lactate and pyruvate in the
brain for both fundamental and clinical research studies.23–25
Microfluidics has attracted a great deal of attention for minia-
turisation of diagnostic devices due to their low analysis
volume, short time for analysis, compact size and low cost26
and is particularly well suited for analysis of the low-volume
flow streams produced with microdialysis.
In addition to monitoring analytes, sampling probes have
also been used to deliver drugs or other substances for phar-
macokinetic and drug metabolism studies in the blood and
various tissues of both animals and humans, and have also
been used to investigate drug distribution to specific
regions.27,28 Retrodialysis using a microdialysis probe could
allow clinicians to deliver carboplatin directly to the tumour
site.
In this study we present a novel microfluidic sensing system
that we envisage being used alongside retrodialysis drug deli-
very into the tumour to detect in real time when carboplatin dis-
perses into surrounding healthy tissue. The concept is shown in
Fig. 1. Development of the detection system involved investi-
gation of the interaction between carboplatin and DNA nucleo-
tides (guanine and adenine) by electrochemical detection of
DNA damage using both a free-solution and on-chip setup. We
have used a novel multiwalled carbon nanotube (MWCNT)-
based composite electrode coupled to diﬀerential pulse voltam-
metry (DPV), which is suitable for working in the low-volume,
high-salt microfluidic environment.
2 Materials and methods
2.1 Materials and reagents
Carboplatin (Sigma-Aldrich) was prepared in 0.1 M acetate
buﬀer (ACB, pH 4.5). T1 perfusate solution was prepared with
147 mM sodium chloride, 4 mM potassium chloride, and
2.3 mM calcium chloride in distilled water and 400 μl of
5-chloro-2-methyl-4-isothiazoline-3-one (Kathon CG, SUPELCO
Analytical, USA) was added as an antibacterial agent. All
chemicals were of analytical grade and obtained from Sigma-
Aldrich. Guanosine 5-monophosphate disodium salt hydrate
(GMP, from yeast, 99%) and adenosine 5-monophosphate
(AMP, from yeast, sodium 99%, premium grade) were obtained
from Sigma-Aldrich. Stock solutions of both 1 mM GMP and
1 mM AMP were dissolved in ACB pH 4.5 as a supporting elec-
trolyte for use in a beaker experiment. In the case of testing
in vitro using an autocalibration system, 1.5 mM AMP was dis-
solved in 0.1 M ACB and T1 solution mixed in the ratio of 3 : 1.
2.2 MWCNT-epoxy composite fabrication
Multiwalled carbon nanotubes (MWCNT, 6–13 nm OD,
2.5–20 μm length) were purchased from Sigma-Aldrich. Epoxy
resin and hardener were obtained from Robnor (RX771C/NC,
and HY1300). The method of MWCNT-epoxy composite fabri-
cation is reported previously by the Patel group,29 although in
the present work we use a diﬀerent ratio of MWCNT : epoxy.
Briefly, plastic pipette tips (10 μl size) were employed to
contain the carbon-epoxy composite. Epoxy resin was prepared
by mixing resin and hardener in the ratio of 3 : 1. The MWCNT
were thoroughly combined with the epoxy resin in the pro-
portion of 1 : 4 by weight and stirred well. A pipette tip was
filled densely with the MWCNT-epoxy composite paste by a
tapping and dragging method. Then an electrical wire was
inserted into the filled pipette and it was allowed to dry at
room temperature for two days. The epoxy resin with the same
ratio as mentioned above was used to fill up the internal
volume of the pipette tip using a 18G hypodermic needle, and
it was allowed to cure for two days. After this process, a scalpel
was used to cut the end of the electrode to expose a surface
area of the MWCNT-epoxy composite that was approximately
Fig. 1 Schematic of an on-line carboplatin detector in healthy tissue
during chemotherapy.
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0.50 mm in diameter. In the microfluidic platform experiment,
MWCNT-epoxy composite electrodes were fabricated using
Radel™ tubing (0.50 mm ID, IDEX) instead of the pipette tip.
2.3 Electrochemical and microfluidic instrumentation
Preliminary experiments were conducted in a small glass
beaker using the MWCNT-epoxy composite electrode as a
working electrode. A coiled Pt wire and a commercial Ag|AgCl
in 3 M NaCl solution (BASi) were used as a counter and a refer-
ence electrode, respectively.
In this work, diﬀerential pulse voltammetry (DPV) was
carried out using Echem software (eDAQ, UK) and a PowerLab
8SP (ADinstruments). Data was processed using Igor Pro
software.
A novel on-line analysis chip was fabricated based on a
microfludic interconnect TEE (Labsmith Inc, USA). A new
channel was drilled to make a cross shape for the outlet
channel and a piece of tube was glued to connect the channel
using Araldite glue. This is shown schematically in Fig. 2. We
estimate the volume between the electrodes to be approxi-
mately 2.6 nanolitres.
3 Results and discussion
3.1 Free-solution experiments
3.1.1 Response of MWCNT-epoxy composite electrode to
GMP and AMP. The electrochemical response of MWCNT-
epoxy composite pipette tip to 1 mM GMP and 1 mM AMP
using diﬀerential pulse voltammetry (DPV) is shown in Fig. 3a
and b for 5 DPV scans. For comparison Fig. 3c and d show the
results for GMP and AMP at a bare GCE.
As seen in Fig. 3c and d, the results showed that the oxi-
dation peaks of both nucleotides (GMP and AMP) were not
stable or reproducible with a GCE. For AMP, the oxidation
peak obtained at the GCE diminished with successive scans
(see Fig. 3d). This agrees with the finding of Piedade19 and is
the reason why Oliveira-Brett’s group modified the glassy
carbon electrode with DNA followed by conditioning with
ssDNA.
Surprisingly, stable oxidation currents were observed within
a few DPV scans at the bare MWCNT-epoxy composite elec-
trode for both AMP and GMP solutions. These DPV voltam-
mograms show prominent oxidation peaks at +1.0 V for GMP
(Fig. 3a) and at +1.30 V for AMP (Fig. 3b). These oxidation
peaks were at almost the same potentials as observed for the
DNA-modified electrode.19
The MWCNT-epoxy composite electrodes gave more stable
oxidation peaks than at GCEs, probably because composite
electrodes provide improved mass transfer and enhanced
electrochemical behaviour.30 There is much in the recent lit-
erature on the advantages of graphene, boron-doped diamond
and carbon nanotube-based electrodes including their fast
electrochemistry, chemical stability and resistance to
fouling.31 Indeed we have recently built an ultra-sensitive flow-
cell for dopamine detection based on metallic single-walled
carbon nanotubes.32 Our choice of a MWCNT-epoxy composite
electrode was a compromise between excellent electrochemical
performance and ease of fabrication into an electrode small
enough to be incorporated into a robust microfluidic cell.
3.1.2 Determination of carboplatin. As bare MWCNT-epoxy
composite electrodes showed such stable electrochemistry for
the free nucleotides we investigated the eﬀect of diﬀerent car-
boplatin concentrations directly on the signals of free GMP
and AMP. The results are shown in Fig. 4. As can be seen, both
GMP and AMP show a clear dose dependency on carboplatin.
For GMP (Fig. 4a) the eﬀect is on both peak and post peak
areas and the use of a baseline between pre- and post-peak
troughs reveals a fall in peak height. The reason for this
complex behaviour is not clear. For AMP (Fig. 4b) a clear fall in
peak height is seen. In Fig. 5 the reduction in peak height is
shown as a function of carboplatin concentration on both
linear (Fig. 5a) and semi-log (Fig. 5b) scales. In Fig. 5a we find
that the AMP peak is more sensitive to carboplatin concen-
tration showing some apparent saturation at higher
concentrations.
To model this behaviour we can consider Kd, which is the
dissociation constant. A reversible binding equilibrium is
shown in eqn (1). In this case, the binding reaction of carbo-
platin (CP) to AMP is shown below:
AMPþ CP Ð AMPCP ð1Þ
For the above reaction, Kd is given by eqn (2).
Kd ¼ ½AMPfree½CP½AMPCP ð2Þ
By balancing the mass of AMP:
½AMP0 ¼ ½AMPfree þ ½AMPCP ð3Þ
Substituting [AMP]free by [AMP]0 − [AMP·CP], the equation
for this case is given in eqn (4)
½AMP0  ½AMPfree ¼
½AMP0½CP
Kd þ ½CP ð4Þ
This [AMP]0 − [AMP]free term corresponds to the loss of
peak height (reduction of oxidation current). The fitted lines
for the GMP and AMP results are shown in Fig. 5a. A value of
Fig. 2 On-line analysis chip (a) photograph of the on-line analysis chip
based on Labsmith TEE component. (b) Schematic of the analysis chip
showing the positions of a combined reference and counter needle
electrode (RE/CE) and a working electrode (WE).
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Kd for carboplatin interacting with AMP was 124.9 ± 17.3 μM.
For GMP, saturation was not reached with the carboplatin con-
centrations used, so it is more diﬃcult to accurately determine
Kd. Nevertheless we can estimate Kd of GMP to be approxi-
mately 398 ± 20 μM. It is quite useful here to plot the data on a
semi-log graph to give the curves shown in Fig. 5b. If we make
the assumption that the interaction between the DNA bases
and carboplatin is a simple binding event then Kd is when log
[carboplatin] is a half. The data in Fig. 5b show that the
sigmoid curve of GMP (dark blue) is shifted to the right reflect-
ing the higher Kd (lower aﬃnity for carboplatin) compared to
AMP. Broadly similar results were found by Oliveira-Brett et al.,
although they found the response saturated at 80 μM carbopla-
tin in the same concentration of AMP using a DNA-modified
GCE.17
We chose AMP for the on-line experiments mainly due to
its greater sensitivity in the 0–100 μM range (Fig. 5). If carbo-
platin concentrations greater than 200 μM had been required,
GMP would have been the preferred substrate. A second advan-
tage of AMP is its simpler electrochemistry as shown in Fig. 4.
Although it is not clear why, the baseline before and after the
oxidation peak of AMP was found to be more stable than for
GMP, as shown in Fig. 4a and b, allowing easier determination
of low concentrations of carboplatin.
3.2 On-chip experimental setup
To realise the on-line analysis capabilities required for the
schematic shown in Fig. 1, we set up a microfluidic-based
system using the same MWCNT-epoxy composite electrode in
a custom-made flow cell (Fig. 2). A combined needle electrode
was used for the counter (stainless steel of the hypodermic
needle) and the reference electrode (50 μm diameter Ag|AgCl
wire). The rest of the analysis system was built using Labsmith
computer-controlled valves and syringe pumps.
Whilst the DNA-base electrochemistry is stable (Fig. 3) and
addition of carboplatin causes the size of the oxidation peak to
decrease (Fig. 4), the latter eﬀect was found to be irreversible.
As a result it was necessary to carefully optimise the analysis
procedure for continuous on-chip detection. We found that
holding the electrode at a negative potential was suﬃcient to
regenerate its electrochemical activity, presumably as a result
of mild electrochemical cleaning.
Fig. 3 DPV voltammograms of stability study at a bare MWCNT-epoxy composite electrode in (a) 1 mM GMP and (b) 1 mM AMP as compared with
at a bare GCE in (c) 1 mM GMP and (d) 1 mM AMP. DPV was performed at a scan rate of 5 mV s−1, pulse amplitude of 50 mV and pulse width of
70 ms. The dotted line indicates as DPV voltammograms obtained using 0.1 M acetate buﬀer at pH 4.5 as a supporting electrolyte.
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Fig. 6a shows the eﬀect of the inter-scan holding potential
on recovery of the electrochemical activity. We find −0.1 V (Ag|
AgCl) provides the best compromise between signal recovery
and maintenance of scan baseline. Addition of this step,
however, increased the time between DPV scans lowering tem-
poral resolution. Therefore, we optimised the duration of the
−0.1 V step, as shown in Fig. 6b and the DPV voltage scan
range as shown in Fig. 6c. The result is a stable measurement
of carboplatin concentration every 170 s. Full details are
described in the ESI.† The schematic of the microfluidic plat-
form for carboplatin calibration is shown in Fig. 7a.
To carry out initial testing on the board, AMP was supplied
to the analysis chip directly from a syringe pump (a*).
Carboplatin dissolved in T1 solution at any concentration
between zero and the syringe concentration of 160 μM is pro-
vided by the careful variation of flow rates of syringes and
control of valves shown in b*. The two solutions mixed at
point ** and were allowed to react for 2 min at 2 μl min−1
using a reaction coil before feeding into the analysis chip.
In Fig. 7b the red dotted line shows the DPV scan for
1.5 mM AMP (on-chip concentration), together with the scans
following mixing of increasing doses of carboplatin.
Pleasingly, a clear dose-dependent reduction of the AMP oxi-
dation peak is seen on-chip, which is approximately linear at
these low concentrations compared to our measured Kd. We
can clearly resolve 10 μM carboplatin, and based on the SD of
the AMP oxidation peaks we estimate the limit of detection is
0.49 μM.
3.3 Microdialysis experiment
The microfluidic system was coupled with an MD probe in
order to validate the capability of detecting carboplatin physio-
logically during cancer chemotherapy. In terms of the sche-
matic shown in Fig. 7a, AMP is supplied from syringe pump
a*, but the carboplatin contained in position b* was not used.
Instead of the carboplatin at b*, the MD stream at point d*
reacts at the mixing point **.
A photograph of the complete system is shown in Fig. 8. An
MD probe (CMA 70, MDialysis, Sweden) was immersed in a
beaker containing 30 ml of T1 solution under stirred con-
ditions. The outlet of the MD probe was connected to the
microfluidic platform and the inlet of the MD probe was
Fig. 4 DPV voltammograms of bare MWCNT-epoxy composite electro-
des for the addition of carboplatin to (a) 1 mM GMP and (b) 1 mM AMP in
0.1 M acetate buﬀer pH 4.5 as a supporting electrolyte at a scan rate of
5 mV s−1, pulse amplitude of 50 mV and pulse width of 70 ms.
Fig. 5 Comparison of the reduction in peak height with addition of
carboplatin for GMP and AMP using bare MWCNT-epoxy composite
electrodes. (a) Data ﬁtted according to eqn (4). (b) Fractional binding of
DNA bases to carboplatin vs. log[carboplatin] μM−1.
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continuously perfused with T1 solution at 0.5 μl min−1 flow rate
using a portable syringe pump (CMA 107, Mdialysis, Sweden).
The T1 solution from the syringe pump flowed continuously
during the experiment in order to allow carboplatin molecules
to diﬀuse through the membrane and to travel in the liquid
Fig. 6 Optimisation of the conditions for detection of carboplatin–
AMP interaction at MWCNT-epoxy composite electrodes. (a) The elec-
trode was held at a negative potential for 2 min between scans to
attempt to regenerate its electrochemical activity. Holding potentials of
−0.1 V, −0.2 V, −0.5 V, −1 V and −2 V were tested. (b) The time that the
electrode was held at −0.1 V and then at 0 V was varied to ascertain the
minimum length of time required at each stage. (c) The eﬀect of short-
ening the DPV scan range was tested to reduce the time required for
each scan. All scans were carried out with a pulse amplitude of 50 mV, a
pulse width of 70 ms and a scan rate of 5 mV s−1.
Fig. 7 (a) Schematic of the microﬂuidic platform for carboplatin cali-
bration. (b) The result of on-chip carboplatin calibration showing DPV
voltammograms performed with a pulse amplitude of 50 mV, a pulse
width of 70 ms and a scan rate of 5 mV s−1.
Fig. 8 Photograph of the experimental setup using the microﬂuidic
platform coupled with an MD sampling probe for carboplatin detection
in real time.
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outlet stream towards the analysis system. The dialysate
interacted with AMP in the microfluidic system and flowed
towards the analysis chip for detection at the WE.
For the dialysate analysis, DPV voltammograms were
obtained when the MD probe was placed in a well-stirred
beaker containing T1 solution. Aliquots of 1 mM carboplatin
standard solution were added to the beaker to give final con-
centrations of 0, 10, 20 and 25 μM.
The dotted line in Fig. 9 shows the DPV obtained in the
absence of carboplatin (0 μM). The decrease in the AMP oxi-
dation peak current corresponding to an external beaker con-
centration of 10 μM was clearly observed (representing an on-
chip concentration of less than this due to microdialysis probe
recovery being less than 100%). The detection limit under
these conditions is 0.014 μM, lower than with on-chip cali-
bration. The reasons for this improvement are not clear. This
experiment is a proof of principle of the carboplatin detection
method.
4 Conclusions
The fabricated microfluidic platform coupled with an MD
probe was successfully used to detect the interaction of carbo-
platin and AMP on-line. A decrease in the oxidation current of
AMP was clearly observed when the dialysate containing carbo-
platin interacted with the AMP solution on the microfluidic
board. We have chosen AMP as it shows greatest sensitivity to
carboplatin. The detection limit of our device is in the appro-
priate range for in vivo carboplatin cytotoxicity measurements.
This fabricated system has potential for development of a clini-
cal device for the detection of carboplatin in real time during
chemotherapy.
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